This Chinese Herb Stock Is Now Bigger Than Super Micro And Reddit

Regencell Bioscience Holdings, a Hong Kong-based biotech startup with no revenue or approved products, has seen its stock price surge over 59,000% in 2025, giving it a market capitalization comparable to Lululemon and exceeding that of Super Micro Computer and Reddit. Despite net losses of $4.36 million and $6.06 million in the last two fiscal years and warnings that it may never be profitable, the stock continues to climb, fueled by social media buzz and a potential share squeeze due to the CEO's 86% ownership.

Analysis

Regencell Bioscience Holdings Ltd. (RGC) has exhibited an extraordinary share price appreciation, surging over 59,000% in 2025 to achieve a market capitalization approaching $30 billion by Monday's close, a valuation that rivals established companies like Lululemon Athletica and exceeds those of Super Micro Computer and Reddit. This meteoric rise, further catalyzed by a 280% increase on Monday alone following a 38-for-1 stock split announced earlier in June, occurs despite a stark absence of supporting fundamentals. The Hong Kong-based biotech startup, which is developing traditional Chinese herbal treatments, has generated no revenue and has not received regulatory approval for any of its products. Financially, Regencell reported net losses of $4.36 million for the fiscal year ending June 2024 and $6.06 million for fiscal year 2023, with company filings explicitly stating it "may never be profitable" and acknowledging a lack of granted patents or distribution capabilities. The extreme price volatility appears to be significantly influenced by substantial social media buzz, where sentiment is mixed, and a potential stock squeeze, given the CEO's reported 86% ownership of outstanding shares. Despite these fundamental concerns, Regencell shares continued to climb, trading up 23% at $73.80 on Tuesday, underscoring a market dynamic driven predominantly by speculative trading rather than intrinsic corporate value.

Key Decisions for Investors

• Investors should recognize the highly speculative nature of Regencell Bioscience (RGC) given its extraordinary stock surge to a multi-billion dollar valuation despite having no revenue, no approved products, and stated uncertainties about future profitability.
• The current price action is likely influenced by social media trends and a potential short squeeze due to high CEO ownership (86%), rather than intrinsic value, indicating substantial risk of sharp corrections.
• Extreme caution is warranted; any exposure should be considered with full awareness of the potential for significant capital loss and the stock's detachment from traditional financial metrics and fundamental business development.